Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin placebo-controlled crossover trial in primary sclerosing cholangitis
ACTRN12621000792820Phase 3Active, not recruiting
- Sponsor
- Princess Alexandra Hospital
- Start
- Jun 2022
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of vancomycin in Primary Sclerosing Cholangitis (PSC) (2 arms), sponsored by Princess Alexandra Hospital. Primary endpoint: Improvement of alkaline phosphatase. Started Jun 2022; status: active, not recruiting.
02
Drugs
vancomycin
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on ACTRN12621000792820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000792820.